Thelansis’s “Idiopathic Membranous Nephropathy (IMN) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Idiopathic Membranous Nephropathy (IMN) is a primary, autoimmune-mediated glomerular disease that stands as a leading cause of nephrotic syndrome in non-diabetic adults. Clinically, it is characterized by massive proteinuria (>3.5 g/day), profound peripheral edema, hypoalbuminemia, hyperlipidemia, and a notably high risk of thromboembolic events, particularly renal vein thrombosis. The underlying pathophysiology involves the subepithelial deposition of IgG4 and complement complexes on the glomerular basement membrane, which triggers podocyte injury and filtration barrier failure. In modern 2026 nephrology, the term "idiopathic" is rapidly being replaced by antigen-specific classifications, as approximately 70–80% of these cases are now known to be driven by circulating autoantibodies against the M-type phospholipase A2 receptor (PLA2R), with another 1–5% targeting THSD7A. Diagnosis relies on serological testing for these biomarkers alongside a renal biopsy demonstrating a classic "spike and dome" morphological pattern. Management is highly risk-stratified, pairing conservative antiproteinuric therapies (such as RAAS blockade) with targeted immunosuppression—most frequently B-cell depleting agents like rituximab—to induce immunological remission and preserve renal function.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Idiopathic Membranous Nephropathy (IMN) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025 report
Our team will get in touch with you shortly about the Idiopathic Membranous Nephropathy (IMN) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025 report.